GALVmed makes livestock vaccines, medicines and diagnostics accessible and affordable to the millions in developing countries for whom livestock is a lifeline
About GALVmed
Neurocysticercosis, a human disease transmitted from pigs with porcine cysticercosis (PC), causes 30% of human epilepsy cases in the developing world.
The disease is estimated to cause around 5 million human cases and 50,000 human deaths each year.
This is a disease that affects the poor and those who have neurocysticercosis are often stigmatised in their communities.
The first-ever licensed PC vaccine became available in India at the end of 2016 at US $1 for 2 doses to vaccinate a pig.
Product development
GALVmed specialises in product development partnerships uniquely established to translate global research progress into tangible livestock disease control tools for the developing world.
Policy and advocacy
The policy environment is a key determinant in the successful translation of research products to livestock health solutions that are sustainably available to smallholder farmers.
On June 8, 2017, the Global Alliance for Livestock Veterinary Medicines (GALVmed) convened a workshop in Kampala, Uganda, aimed at presenting the findings on the safety and protection of East Coast Fever-Infection Treatment Method (ECF-ITM) …
Collectively, smallholder poultry farmers around the world provide a large market for livestock veterinary products. But this crucial segment has traditionally been unserved by pharmaceutical companies, often because smallholder markets are viewed as non-profitable and …
Porcine Cysticercosis is a serious zoonotic disease prevalent in many parts of the world especially in developing countries, where sanitation remains a challenge. It causes 30% of human epilepsy cases in the developing world.
A GALVmed-led …
